|
|
 |
|
Viewing report
|
|
|
|
Optimizing Genomics Asset Management for High ROI - Evaluating Strategies to Support the Bio/Pharma Value Chain
Datamonitor, Oct 2004, Pages: 90
The need to overcome the pharma industry’s pipeline productivity crisis is forcing the genomics innovators and their partners to reshape their portfolio management. New asset allocation strategies and valuation methodologies are needed to support the evolution to a new business model emphasizing investment in technological diversification.
This report considers the evolution of the genomics sector, through an evaluation of the trends extracted from the key licensing, drug development and M&A deals. We reveal the challenges lying ahead for both innovators and their partners. Vital steps to integrate newly diversified genomics assets into the bio/pharma value chain are introduced followed by a novel way to assess the value of genomics innovation. The new asset valuation platform is based on blending quantitative real option methodologies and qualitative multidimensional asset analyses.
Scope of report:
- Insight into the dynamics of the genomics sector, as it diversifies to meet the challenge of the evolving bio/pharma supply chain
- Survival strategies for potential postgenomics drug developers and successful exit strategies for failed genomics businesses
- Novel portfolio management and option based asset valuation to support postgenomics drug developers, genomics licensees and innovators
Highlights:
- The early wave of the genomics revolution witnessed a spectacular stock value decline. This was caused by the lack of transparency between the industrys innovating, investing and licensing arms, and by a high degree of speculation related to unrealistic market generation targets and lack of understanding of the technological complexities.
- The new wave of innovation is focusing on gene functionalities, population genomics, chemo- and pharmacogenomics. Drug developers should continue integrating well-defined genomics assets into their supply chains, work to maximize successful target validation and optimize alliance networks to ensure asset co-evolution and diversification.
- Conventional discount flow-based asset valuation cannot describe the complexity of each genomics asset. Therefore, blending quantitative real option based and qualitative multifactorial asset analysis models can offer flexible long-term asset allocation and a number of capital growth opportunities hidden in genomics assets.
Reasons to Purchase:
- Understand the dynamics behind the early genomics devaluation, and develop winning business survival and successful postgenomics exit strategies
- Gain insight into how the new wave of genomics diversification helps the bio/pharma supply chain to recover from its current productivity crisis
- Improve genomics project valuation by combining novel multidimensional asset analysis for less supply chain complexity, with real option based methods
Customers who bought this item also bought
Optimizing Genomics Asset Management for High ROI - Evaluating Strategies to Support the Bio/Pharma Value Chain
Pharmaceutical Sales Force Strategies: Driving ROI Through Best Practice In Targeting, Management, Outsourcing And Technologies
Systems Biology - Key to Unlocking the Value within the Omics Revolution
Optimizing Portfolio Management: Strategies to Deliver Corporate Success
Improving Sales Force Effectiveness: Evaluating the ROI of technology solutions in the pharmaceutical industry
The Pharmaceutical Sales Force Outlook: Structures And Strategies To Maximize ROI And Boost Product Uptake
Asthma Disease Management: Strategies, Trends and ROI, Live Audio Conference on CD-ROM
Optimizing Licensing Strategies for the 21st Century: Creating Win-Win Pharmaceutical and Biotech Licensing Deals
|
|
|
|
